Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China
– First glucokinase-activator (GKA) approval outside mainland China– Approval supports a differentiated approach to Type 2 diabetes (T2D) management– Hong Kong will serve as Hua Medicine’s launchpad for international market expansion SHANGHAI, HONG KONG, Mar 3, 2026 – (ACN Newswire via SeaPRwire.com) – Hua Medicine (“the Company”, Hong Kong Stock Exchange Stock Code: 2552.HK) announced today […]



















